"8-11 hours in adults with normal renal function"@en . . "Take on empty stomach: 1 hour before or 2 hours after meals."@en . . . . . . . . . . . . "Readily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF. "@en . . . "LD₅₀=4850 (orally in mice)"@en . . . . . . . . . . "2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine"@en . "# Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8195839 # Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8071675 # Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16150859 # Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12239226 # Johnson JR, Manges AR, O'Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12103291"@en . "Gram negative and gram positive bacteria"@en . . . . . "738-70-5"@en . . . . . . . . . . . . . "Trim\u00E9thoprime"@en . . . . . . . . . . . "42-46% bound to plasma proteins"@en . . . . . . . . "Escherichia coli"@en . . . . . . . . . . . . . . . . . "Yasushi Takagishi, Kiichiro Ohsuga, Sadao Ohama, \"Suppository containing sulfamethoxazole/trimethoprim complex and process for preparing the same.\" U.S. Patent US4461765, issued December, 1975."@en . . . "Trimethoprimum"@en . "Trimethoprim"@en . "For the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea."@en . . . . . . . . . . . . "Trimethoprim"@en . . . . . . " "@en . . . . . . . "Listeria monocytogenes"@en . . . "Take with a full glass of water."@en . "Trimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF). THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis. Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase. Sulfamethoxazole inhibits dihydrofolate synthetase (aka dihydropteroate synthetase), an enzyme involved further upstream in the same pathway. Trimethoprim and sulfamethoxazole are commonly used in combination due to their synergistic effects. This drug combination also reduces the development of resistance that is seen when either drug is used alone."@en . . . . . . . . . . . . . . "Proloprim"@en . . . . . . "A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim resistance has been reported. [PubChem]"@en . . . . . . . . "approved"@en . . . . . . . "Trimetoprima"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine"@en . . . . . . "Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim. Trimethoprim also passes the placental barrier and is excreted in human milk."@en . . . . . . "Trimpex"@en . . . . . . . . . . . . . . . . . . "Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication."@en . .